Intermittent Fasting Tested as a Tool to Slow Chronic Lymphocytic Leukemia
A Phase 1 trial examines whether time-restricted eating can reduce cancer cell counts and modulate autophagy in CLL patients.
Summary
Researchers at BC Cancer launched a Phase 1 trial to investigate whether intermittent fasting — specifically time-restricted feeding — can slow the progression of chronic lymphocytic leukemia (CLL), the most common chronic leukemia in adults. Participants followed a structured fasting protocol, dividing their day into fasting and eating windows without mandatory caloric restriction, supported by an oncology dietitian. Over three months, investigators measured blood lymphocyte counts as a direct cancer marker, alongside quality-of-life questionnaires and laboratory analysis of autophagy and inflammatory markers. The study is particularly relevant to longevity science because CLL is incurable and dietary strategies represent a low-cost, low-risk complementary approach. Prior evidence suggests fasting can reduce cancer risk and improve chemotherapy tolerance, and this trial seeks to determine if it can directly influence cancer cell burden.
Detailed Summary
Chronic lymphocytic leukemia is the most common chronic leukemia in adults and remains incurable, making alternative management strategies an urgent priority. This Phase 1 clinical trial, conducted at BC Cancer's Deeley Research Centre, represents one of the first attempts to systematically evaluate intermittent fasting as a direct intervention in a cancer population — moving beyond observational data into prospective human testing.
The trial enrolled CLL and small lymphocytic lymphoma (SLL) patients and assigned them to a time-restricted feeding protocol — essentially compressing daily food intake into a defined eating window, similar to skipping or delaying breakfast. Participants were not required to reduce total caloric intake, isolating the timing effect from caloric restriction. An oncology dietitian guided each participant through a transition period before the full protocol began.
The primary outcome was change in blood lymphocyte count over three months, a reliable, easily measurable surrogate for cancer burden in CLL. Secondary outcomes included quality-of-life assessments and laboratory investigation of autophagy activity and inflammatory markers — two mechanisms hypothesized to underlie fasting's potential anti-cancer effects. Autophagy, the cellular self-cleaning process, is known to be dysregulated in CLL and may be upregulated by fasting.
The rationale draws on robust preclinical and epidemiological data showing that fasting reduces cancer incidence, extends lifespan in animal models, and in cancer patients undergoing chemotherapy, reduces short-term side effects such as nausea, fatigue, and sleep disruption. Whether it can directly alter cancer cell kinetics in humans is an open and critically important question.
The trial has completed. Caveats include small expected sample size typical of Phase 1 designs, the absence of a randomized control arm in this initial phase, and the summary here is based on the abstract and registry description only, not published results.
Key Findings
- Phase 1 trial tested time-restricted feeding in CLL patients without requiring caloric restriction over 3 months.
- Primary measure was blood lymphocyte count — a direct, easily tracked surrogate for cancer burden in CLL.
- Autophagy and inflammatory markers were assessed in the lab as potential mechanisms linking fasting to cancer control.
- Prior trials show fasting reduces chemotherapy side effects including nausea, fatigue, and sleep disruption.
- If effective, findings could open the door to integrating dietary timing into formal cancer treatment protocols.
Methodology
Phase 1 prospective interventional trial enrolling CLL/SLL patients in a time-restricted feeding protocol supported by an oncology dietitian, with no mandatory caloric restriction. Primary endpoint was change in blood lymphocyte count over 3 months; secondary endpoints included quality-of-life questionnaires and laboratory measurement of autophagy and inflammation at BC Cancer's Deeley Research Centre. The trial status is listed as completed, but published results are not yet available from the registry entry.
Study Limitations
This is a Phase 1 trial with an expected small sample size, limiting statistical power to detect modest effects. No randomized control arm is described in the registry entry, making it difficult to distinguish fasting effects from natural disease fluctuation. The summary is based on the abstract and clinical trial registry description only, as full published results were not available — key outcome data cannot be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: